Researchers from the University of Pittsburgh have developed a new way to grow T cells in the lab that enables them to live ...
Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties. BioWorld Asia Deals and M&A Immune Antibody ...
This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta’s cell therapy product, ...
This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence ... at INNOVIT - Italian Innovation and Culture Hub in San Francisco.
This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta's cell therapy product, ensuring ...
This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence ... at INNOVIT – Italian Innovation and Culture Hub in San Francisco.
MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has ...
JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...
Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...